ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2512

Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis
Abstract Number: 2331

Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Abstract Number: 1947

Coronary computed tomography incidental findings in rheumatoid arthritis.
Abstract Number: 2531

Coronary periarteritis in IgG4-Related Disease
Abstract Number: 1957

Correlates Between Cardiovascular Risk Scores with Coronary Microvascular Function and Plaque Burden in Rheumatoid Arthritis
Abstract Number: 2291

Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren’s Disease
Abstract Number: 2388

Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study
Abstract Number: 0348

Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
Abstract Number: 1620

Correlation Between Histopathological Findings and PET-CT Results in Patients With Inflammatory Aortitis
Abstract Number: 1772

Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases
Abstract Number: 2330

Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study
Abstract Number: 1940

Correlation of Hand and Lymphatic Function Post Exercise Intervention in Rheumatoid Arthritis
Abstract Number: 1931

COSMOS Prevalence of aTTP in SLE
Abstract Number: 1366

Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
Abstract Number: 2111

Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].